Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
Completed · Phase 1
Conditions studied: Oncology
In brief
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate) relative to matched, healthy controls.
Key facts
- Study ID
- NCT02521376
- Run by
- Gilead Sciences
- People needed
- 56
- Starts
- 2015-11-16
- Expected to finish
- 2017-10-25
- Last updated by the study team
- 2019-07-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Pharmacology of Miami, Inc. (CPMI) — Miami, Florida, United States
- Orlando Clinical Research Center — Orlando, Florida, United States
- DaVita Clinical Research — Minneapolis, Minnesota, United States
- The Texas Liver Institute — San Antonio, Texas, United States
- APEX GmBH — Munich, Germany
- Auckland Clinical Studies — Auckland, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.